DiaSorin nabs FDA clearance for infectious disease blood test

By The Science Advisory Board staff writers

July 22, 2022 -- Saluggia, Italy-based DiaSorin on Friday announced that it has obtained U.S. Food and Drug Administration (FDA) clearance for the Liaison MeMed BV, its host-protein signature-based assay.

The fully automated test utilizes host response-based data to enable physicians to differentiate accurately between bacterial and viral infections, supporting faster and better-informed treatment and patient management decisions, DiaSorin said.

The test also drives laboratory operational efficiency through time-labor reduction by using a fully automated and high-throughput approach when compared with traditional growth-based microbiology methods, the firm added.

The company said it is launching the blood-based assay in the U.S. and noted that the launch follows a licensing agreement inked with MeMed in September 2020.

Under the agreement, DiaSorin obtained the rights to commercialize and make the MeMed BV test available on its large installed base of Liaison platforms.

The test provides a valuable tool in the growing global threat posed by antimicrobial resistance, DiaSorin said.

The firm announced the clearance ahead of AACC 2022 in Chicago.


Copyright © 2022 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.